Treatment of idiopathic pituitary dwarfism with methionyl human growth hormone

Endocrinol Jpn. 1983 Aug;30(4):523-7. doi: 10.1507/endocrj1954.30.523.

Abstract

Ten patients with idiopathic pituitary dwarfism were treated with methionyl human growth hormone (met-hGH) produced by recombinant DNA technology. They were given 0.5 IU/kg/week of met-hGH for three months. There were no significant changes in physical, blood, urine examinations. Their height increased between 1.5 and 2.7 cm during the 3 months of treatment, which was calculated to be equivalent 6.0 and 10.8 cm per year with a mean increase of 8.7 cm. Anti-hGH antibody was observed in all patients between one and two months of treatment with a titer between 10(1)X and 10(4)X. In spite of the formation of antibodies, the growth rate did not decrease in 7 of the 10 cases.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adolescent
  • Antibodies / analysis
  • Child
  • Dwarfism, Pituitary / drug therapy*
  • Female
  • Growth Hormone / analogs & derivatives*
  • Growth Hormone / immunology
  • Growth Hormone / therapeutic use
  • Human Growth Hormone
  • Humans
  • Male

Substances

  • Antibodies
  • Human Growth Hormone
  • Growth Hormone